EuroBiotech Report—Roche SMA data, iOnctura, PDC*line, Targovax and Bayer

Map of Europe
(Pixabay)

Welcome to the latest edition of our weekly EuroBiotech Report. We start this week with Roche, which took a step toward challenging Biogen and Novartis for the spinal muscular atrophy market by bringing risdiplam through another late-phase test. Elsewhere, European biotechs rased cash, with Merck KGaA spinout iOnctura reeling in €15 million and PDC*line Pharma securing €13.9 million. Targovax outlined plans to test ONCOS-102 in combination with a checkpoint inhibitor, despite early-phase data leaving scope to question the efficacy of the drug. Bayer CEO Werner Baumann  offered his views on gene editing. And more. — Nick Taylor
 
1. Roche's risdiplam clears another phase 3 SMA trial

Roche’s risdiplam has come through another late-phase test, triggering improvements in the motor skills of infants with type 1 spinal muscular atrophy. The clinical success comes months before the FDA is set to decide whether to approve the survival motor neuron-2 splicing modifier.
 
2. Merck KGaA-spinout iOnctura raises cash for cancer trials

Merck KGaA spinout iOnctura has raised a €15 million ($17 million) series A round to support an early-phase solid tumor trial. The company is gearing up to generate data on PI3Kδ inhibitor IOA-244 in humans while hustling a second candidate through IND-enabling studies.
 
3. Korean VCs pile into PDC*line to bankroll NSCLC vaccine trial

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

PDC*line Pharma has turned to Korean investors to help raise a €13.9 million ($15.5 million) series B round. The money will fund a phase 1/2 trial of a therapeutic vaccine in patients with non-small cell lung cancer that got underway last year.
 
4. Targovax plans checkpoint combo trial after posting early data on oncolytic virus

Targovax has shared data from an early-phase trial that administered ONCOS-102 to mesothelioma patients. The response rate was lower in the ONCOS-102 arm than in the control cohort, but Targovax saw positives elsewhere, leading it to outline plans to pair the drug with a checkpoint inhibitor.
 
5. 'Does intrinsically good and bad technology exist?' Bayer CEO says no: Davos 2020

Bayer CEO Werner Baumann highlighted “less and less trust in society for advances in technology” as a hurdle for pharma companies working on gene editing during a panel on genetic modification and engineering that took place at the World Economic Forum meeting in Davos, Switzerland. 
 
And more articles of note>> 

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.